EP Patent

EP3700531B1 — Dosage regimen of paliperidone palmitate extended-release injectable suspension

Assigned to Geneora Pharma Shijiazhuang Co Ltd · Expires 2025-06-25 · 1y expired

What this patent protects

Patent listed against Invega Sustenna.

Drugs covered by this patent

Invega Sustenna (PALIPERIDONE PALMITATE) · Johnson & Johnson

Patent Metadata

Patent number: EP3700531B1
Jurisdiction: EP
Classification: —
Expires: 2025-06-25
Drug substance claim: No
Drug product claim: No
Assignee: Geneora Pharma Shijiazhuang Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.